regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-31. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
=== Polypeptide hormones, toxins, and antimicrobial peptides === Many hormones, toxins, inhibitors, or antimicrobial peptides interact specifically with transmembrane protein complexes. They can also accumulate at the lipid bilayer surface, prior to binding their protein targets. Such polypeptide ligands are often positively charged and interact electrostatically with anionic membranes. Some water-soluble proteins and peptides can also form transmembrane channels. They usually undergo oligomerization, significant conformational changes, and associate with membranes irreversibly. 3D structure of one such transmembrane channel, α-hemolysin, has been determined. In other cases, the experimental structure represents a water-soluble conformation that interacts with the lipid bilayer peripherally, although some of the channel-forming peptides are rather hydrophobic and therefore were studied by NMR spectroscopy in organic solvents or in the presence of micelles.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
== Bibliography == J. Samuel Walker (November 1, 2000). Permissible Dose: A History of Radiation Protection in the Twentieth Century. University of California Press. ISBN 978-0-520-92484-0. Limited preview in Google Books. K. N. Govinda Rajan (July 28, 2017). Radiation Safety in Radiation Oncology. CRC Press. ISBN 978-1-4987-6226-7. Limited preview in Google Books. Strahlengefahrdung und Strahlenschutz / Radiation Exposure and Radiation Protection. Springer-Publisher. March 13, 2013. ISBN 978-3-642-82229-2. Limited preview in Google Books J. Samuel Walker (April 2001). Short History of Nuclear Regulation, 1946–1999. DIANE Publishing. ISBN 978-0-7567-0929-7.Limited preview in Google Books. Ashley W. Oughterson, Shields Warren: Medical Effects of the Atomic Bomb in Japan. Volume VIII.8 aus der National Nuclear Energy Series zum Manhattan Project, McGraw-Hill Book Company, 1956. Carl Voegtlin, Harold C. Hodge: Pharmacology and Toxicology of Uranium Compounds. Volume VI.1, Part I and Part II (with a Section on the Pharmacology and Toxicology of Fluorine and Hydrogen Fluoride) from the National Nuclear Energy Series to the Manhattan Project, McGraw-Hill Book Company, 1949. Henry DeWolf Smyth (written on the request of Maj. Gen. L. R. Groves): Atomic Energy for Military Purposes. The official report on the development of the atomic bomb under the auspices of the United States Government, 1940–1945. Princeton University Press, 1946. James E. Grindler (Argonne National Laboratory): The Radiochemistry of Uranium.
Sources: en.wikipedia.org
In 1775, the Continental Congress determined a ration that included either one pound (450 g) of beef, three-quarters pound (340 g) of pork, or one pound (450 g) of salted fish per day, as well as one pound (450 g) of flour or bread per day, one pint of milk per day, one quart of spruce beer or cider per day, three pounds (1.4 kg) of peas or beans per week, one pint of rice per week, and a small amount of molasses. However, in reality, the Continental Army had difficulties supplying its units. Congress lacked the authority to raise sufficient taxes and transportation and other supply issues compounded the problem. In reality, soldiers might receive some flour and perhaps a small amount of meat or fish. In order to preserve the food, meat was often salted and the flour would often be baked into hard biscuits. As these rations had hardly any nutrients, a weekly ration of vinegar or sauerkraut was eventually added to try to prevent scurvy, but this was insufficient. Sometimes days would pass between rations. Soldiers had to resort to foraging, with those who understood the local vegetation being able to find food in woods around the camps. At Valley Forge, watercress and sorrel were sometimes foraged to provide the troops with some vegetables. Soldiers at times had to hunt whatever animals they could find and beg civilians for food. They also bought food when possible, but this proved difficult as the Continental Army mostly paid in promissory notes which were widely distrusted and many soldiers had little goods or money to trade.
Energy of about 6 MeV provided by the incident neutron was necessary to overcome this barrier and cause the nucleus to fission. According to John Lilley, "The energy required to overcome the barrier to fission is called the activation energy or fission barrier and is about 6 MeV for A ≈ 240. It is found that the activation energy decreases as A increases. Eventually, a point is reached where activation energy disappears altogether...it would undergo very rapid spontaneous fission." Maria Goeppert Mayer later proposed the nuclear shell model for the nucleus. The nuclides that can sustain a fission chain reaction are suitable for use as nuclear fuels. The most common nuclear fuels are 235U (the isotope of uranium with mass number 235 and of use in nuclear reactors) and 239Pu (the isotope of plutonium with mass number 239). These fuels break apart into a bimodal range of chemical elements with atomic masses centering near 95 and 135 daltons (fission products). Most nuclear fuels undergo spontaneous fission only very slowly, decaying instead mainly via an alpha-beta decay chain over periods of millennia to eons. In a nuclear reactor or nuclear weapon, the overwhelming majority of fission events are induced by bombardment with another particle, a neutron, which is itself produced by prior fission events. Fissionable isotopes such as uranium-238 require additional energy provided by fast neutrons (such as those produced by nuclear fusion in thermonuclear weapons).
The general structure of the endoplasmic reticulum is a network of membranes called cisternae. These sac-like structures are held together by the cytoskeleton. The phospholipid membrane encloses the cisternal space (or lumen), which is continuous with the perinuclear space but separate from the cytosol. The functions of the endoplasmic reticulum can be summarized as the synthesis and export of proteins and membrane lipids, but varies between ER and cell type and cell function. The quantity of both rough and smooth endoplasmic reticulum in a cell can slowly interchange from one type to the other, depending on the changing metabolic activities of the cell. Transformation can include embedding of new proteins in membrane as well as structural changes. Changes in protein content may occur without noticeable structural changes.
=== Accumulation in buildings === Measurement of radon levels in the first decades of its discovery was mainly done to determine the presence of radium and uranium in geological surveys. In 1956, most likely the first indoor survey of radon decay products was performed in Sweden, with the intent of estimating the public exposure to radon and its decay products. From 1975 up until 1984, small studies in Sweden, Austria, the United States and Norway aimed to measure radon indoors and in metropolitan areas.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.